L19-TNF and other TNF-based fusion proteins were found to be potently active against soft-tissue sarcoma and the fully-human fusion protein is currently being studied in pivotal trials in this indication, in combination with doxorubicin (NCT03420014, Eudract no. 2016-003239-38). Here, TNF is linked to soft tissue sarcoma.